Diagnostic Assessment Report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Clinical Excellence – protocol

Title of project

Testing strategies for Lynch syndrome in people with endometrial cancer

Name of External Assessment Group (EAG) and project lead

Produced by:	Warwick Evidence
Authors:	Chris Stinton
	Mary Jordan
	Peter Auguste
	Hannah Fraser
	Rachel Court
	Lena Alkhudairy
	Jason Madan
	Dimitris Grammatopoulos
	Sian Taylor-Phillips
Correspondence to:	Dr Sian Taylor-Phillips
	Associate Professor
	Division of Health Sciences
	Warwick Medical School
	University of Warwick
	Coventry CV4 7AL
Tel:	02476 575882
Email:	s.taylor-phillips@warwick.ac.uk
Date completed:	7 th August 2019
The views expressed in	n this protocol are those of the authors and not necessarily those of the NIHR

HTA Programme. Any errors are the responsibility of the authors. The authors have no conflicts of interest.

Glossary of terms

CEAC	Cost-effectiveness acceptability curves
CRD	Centre for Reviews and Disseminations
DAC	Diagnostic Advisory Committee
DARE	Database of Abstracts of Reviews of Effects
DNA	Deoxyribonucleic acid
EAG	External Assessment Group
HNPCC	Hereditary non-polyposis colorectal cancer
HTA	Health Technology Assessment
IHC	Immunohistochemistry
LY	Life-years
MLH1	MutL homologue 1
MLH2	MutS homologue 2
MLPA	Multiplex ligation-dependent probe amplification
MSH6	MutS homologue 6
MSI	Microsatellite instability
NGS	Next generation sequencing
NICE	The National Institute for Health and Care Excellence
QALY	Quality-adjusted life-years
PMS2	Postmeiotic segregation increased 2
ROB 2	A revised tool to assess risk of bias in randomized trials
ROBINS-I	Risk Of Bias In Non-randomized Studies of Interventions
ROC	Receiver operating characteristic
WTP	Willingness-to-pay

1. Plain English Summary

Lynch syndrome is an inherited condition that is caused by a problem in our genes. People who have Lynch syndrome have a higher risk of some types of cancers (such as bowel and womb cancers) than people who do not have it. It runs in families and a person with Lynch syndrome has a 50:50 chance of passing it on to their children. Identifying Lynch syndrome could stop cancers developing, lead to earlier treatment for cancers, and help to find other family members who might have it. Currently, NICE guidance recommends testing for Lynch syndrome in people who have bowel cancer. Testing for Lynch syndrome amongst people who have womb cancer is not usually carried out, or may only be done when they have a history of Lynch syndrome in their family, or if they have been diagnosed with womb cancer at a younger age (under 50). The main ways to identify if someone who has cancer is at higher risk of having Lynch syndrome are (1) immunohistochemistry and (2) microsatellite instability-based tests. Immunohistochemistry looks for missing proteins, and microsatellite instability testing looks for changes in the patterns of our DNA. The missing proteins and changes to DNA are associated with Lynch syndrome-related cancers. Other tests can help to rule out cancers that are not caused by Lynch syndrome. People found to be at higher risk of Lynch syndrome by either of the two tests can be given extra tests to diagnose the condition. The aim of the current project is to review the clinical and cost-effectiveness of testing for Lynch syndrome amongst people who have endometrial cancer, and their biological relatives.

2. Decision problem

2.1 Purpose of the decision to be made

Lynch syndrome is an inherited genetic condition. It is caused by mutations in genes that are involved in repairing errors that occur in DNA when cells replicate. When mutations occur in these genes, DNA errors are not repaired. Over time, this can lead to uncontrolled cell growth. Lynch syndrome is associated with an increased risk for cancers, including colorectal, endometrial, gastric, pancreatic, and kidney cancers. There is 50:50 chance that a person with Lynch syndrome will pass it to their children.

Recently NICE has recommended that people who are diagnosed with colorectal cancer are tested for Lynch syndrome [DG27].¹ Routine testing for Lynch syndrome amongst people with endometrial cancer is not currently conducted. Detection of Lynch syndrome might lead to reductions in the risk of developing cancer for both the individual and their family members (through surveillance and risk-reducing strategies such as chemoprevention) and earlier treatment of cancers.^{2,3}

The External Assessment Group (EAG) will assess the accuracy of immunohistochemistry and microsatellite instability-based testing strategies to identify people who are at high risk of Lynch syndrome, and the clinical and cost-effectiveness of testing for Lynch syndrome amongst people who

have endometrial cancer and their biological relatives. This will inform the NICE Diagnostic Advisory Committee (DAC) guidance on whether testing for Lynch syndrome in people who have endometrial cancer represents a cost-effective use of NHS resources.

2.2 Population and target condition

2.2.1 Population: People with endometrial cancer

Endometrial cancer (cancer that develops from the lining of the uterus) is the most common gynaecological cancer in the Western world.⁴ Endometrial cancer starts to occur when the cells of the endometrium grow very rapidly. This causes the lining of the uterus to thicken in certain areas, which may form a mass of tissue known as tumour. Each year in the UK, there are approximately 9,300 new cases of endometrial cancer and 2,200 endometrial cancer-related deaths.⁵ The incidence of endometrial cancer generally increases with age, reaching a peak of 97.3 per 100,000 population between the ages of 75 and 79 years.⁵ The most recent estimates suggest that people with endometrial cancers have a 1-year survival rate of 89.6% and a 5-year survival rate of 75.7%.⁶ Risk factors for the development of endometrial cancer include obesity, nulliparity, early age at menarche, use of hormone-replacement therapy, and Lynch syndrome.⁷⁻⁹

2.2.2. Target condition: Lynch syndrome

Lynch syndrome, formally called hereditary non-polyposis colorectal cancer (HNPCC), is a cancerpredisposition syndrome. It is estimated that there are approximately 175,000 people with Lynch syndrome in the UK.¹⁰

Lynch syndrome is usually caused by mutations to any one of four DNA mismatch repair (MMR) genes: MLH1 (MutL homologue 1), MSH2 (MutS homologue 2), MSH6 (MutS homologue 6), or PMS2 (postmeiotic segregation increased 2).¹¹ A small proportion of Lynch syndrome cases are caused by deletions to the EPCAM gene, which leads to epigenetic silencing of MSH2.¹¹ MMR genes encode proteins that are involved in recognising and repairing errors that occur in DNA during cell division. Mutations in MMR genes prevent DNA errors from being corrected. This can lead to uncontrolled cell growth and the development of cancer. A range of cancers has been associated with Lynch syndrome, the most common of which are endometrial and colorectal.¹² Lynch syndrome accounts for 2 - 9% of endometrial cancers.^{13,14} By the age of 75, approximately 57% of people with Lynch syndrome will have endometrial cancer.¹² The type and prevalence of cancer appears to vary according to which of the genes are affected.¹²

Lynch syndrome has an autosomal dominant inheritance pattern, meaning that a person has a 50 per cent chance of passing the mutated gene(s) onto their children.

2.3 Interventions

The two main approaches to identifying people who are at higher risk of Lynch syndrome are described below. Both tests are conducted on tumour tissue.

2.3.1 Immunohistochemistry

Immunohistochemistry (IHC) uses antibodies to look for the expression of four MMR proteins (MLH1, MSH2, MSH6 and PMS2). An absence of staining for any of the proteins suggests a genetic mutation. IHC testing identifies which MMR gene is potentially affected. If MLH1 has an abnormal expression, an additional test (MLH1 promoter hypermethylation testing) can be conducted (see section 2.3.3). IHC can detect non-functional but antibody-binding MLH1 proteins (which would be incorrectly classified as normal),¹⁵ therefore this may lead to a false negative result.

2.3.2 Microsatellite instability testing

Microsatellites are short repeats of DNA sequence. These repeats are prone to acquiring errors. When the MMR genes are not functioning these errors are not corrected. Mutations in MMR genes lead to variations in the size of these repeats. This is called microsatellite instability (MSI). MSI testing is used to determine if there are differences in the repeat numbers between tumour and non-tumour regions of a person being tested. Various markers have been described.¹⁶ The Bethesda guidelines identifies 5 markers (BAT25, BAT26, DS123, D17S250 and D5S346) for MSI for Lynch syndrome.¹⁷ Typically, three classifications are derived from this approach:

- MSI-high two or more markers show instability/more than 30% of markers show instability.
- MSI-low 1 marker shows instability/less than 30% of markers show instability.
- MSI-stable 0 markers show instability.

Additional testing can be conducted to help rule out sporadic epigenetic silencing of MLH1 which might present as Lynch syndrome (see section 2.3.3 - MHL1 promoter hypermethylation testing).

2.3.3. MLH1 promoter hypermethylation testing

Hypermethylation is an epigenetic process that switches off the expression of proteins. MLH1 promoter hypermethylation testing is conducted on tumours. A positive result on this test suggests the tumour is sporadic and not a result of Lynch syndrome. However, there is some evidence that constitutional epimutations of MLH1 in normal tissue may be a cause of Lynch syndrome in a small number of cases.¹⁸

2.4 Diagnostic test

Currently, there is no single test that is used to identify all cases of Lynch syndrome. Typically, Lynch syndrome is diagnosed on the basis of constitutional mutations (i.e. mutations that are present in every cell) in MMR genes, which involves sequencing (including next-generation sequencing, NGS) to detect point mutation, small insertions or deletions in these genes, and multiplex ligation-dependent probe amplification (MLPA) to detect larger structural changes (such as deletions, duplications or rearrangements) to genetic sequences that could be missed by sequencing alone. Sequencing and MLPA may be used in combination to diagnose Lynch syndrome. However, these techniques also detect novel sequence variation in MMR genes that are of unknown significance. Sequencing of *tumours* can be used to identify sporadic tumours (i.e. those not caused by Lynch syndrome). If a person has deficient MMR (from tumour testing) but no germline mutation is identified and no somatic cause is identified, they can be considered to have Lynch-like syndrome (also known as putative or cryptic Lynch syndrome). Additional testing has been suggested in cases where tumour testing is positive but no Lynch syndrome-related pathogenic variant are identified.^{19,20} This includes testing for other somatic or germline pathogenic variants (e.g. biallelic MuTYH, POLE, double somatic MMR variants).

2.5 Care pathway

NICE has published guidance on testing for Lynch syndrome amongst people diagnosed with colorectal cancer [DG27]¹. Currently, there is no NICE guidance for testing for Lynch syndrome in people who have endometrial cancer. The NHS National Genomic Test Directory provides testing criteria for people who have Lynch syndrome-related cancers.²¹ In brief, testing is recommended in people who have a family history of Lynch syndrome-related cancers or who have been diagnosed with endometrial cancer below the age of 50. The 11 proposed testing pathways for the current review are outlined in figures 1–11 below.



Figure 1: Strategy 1: MSI testing alone (MSS: microsatellite stable, MSI: microsatellite instability, LS: Lynch syndrome)



Figure 2: Strategy 2: MSI testing with MLH1 promoter hypermethylation testing (*if a germline sample is tested and is also hypermethylated diagnose Lynch syndrome)



Figure 3: Strategy 3: IHC-based testing (LS: Lynch syndrome)



Figure 4: Strategy 4: IHC testing with MLH1 promoter hypermethylation testing (*if a germline sample is tested and is also hypermethylated diagnose Lynch syndrome)



Figure 5: Strategy 5: MSI testing followed by IHC testing



Figure 6: Strategy 6: MSI followed by IHC testing with MLH1 promoter hypermethylation testing (*if a germline sample is tested and is also hypermethylated diagnose Lynch syndrome)



Figure 7: Strategy 7: IHC followed by MSI testing



Figure 8: Strategy 8: IHC testing followed by MSI testing with MLH1 promoter hypermethylation testing (*if a germline sample is tested and is also hypermethylated diagnose Lynch syndrome)



Figure 9: Strategy 9: MSI and IHC testing



Figure 10: Strategy 10: MSI and IHC testing with MLH1 promoter hypermethylation testing (*if a germline sample is tested and is also hypermethylated diagnose Lynch syndrome, ** MLH1 promoter hypermethylation testing not conducted after MSI if MLH1 expression on IHC is normal and abnormal expression of other MMR proteins is present)

Germline testing for LS

Figure 11: Strategy 11: Germline testing only

Possible diagnostic pathways and approaches to the management of Lynch syndrome have been suggested by a range of societies and expert groups, including the British Gynaecological Cancer Society,²² the European HNPCC Expert group,²³ the Royal College of Obstetricians and Gynaecologists,²⁴ and the Manchester International Consensus Group.²⁰ There is some evidence that daily aspirin,²⁵ and prophylactic hysterectomy and bilateral salpingo-oophorectomy reduce the risk of endometrial and ovarian cancers.²⁶ Colorectal cancer surveillance is associated with a decreased risk of colorectal cancer incidence and mortality.²⁷ It is unclear if gynaecological surveillance is beneficial.²⁸

3 Decision questions and objectives

3.1 Decision questions

The overall objectives of this project are to examine the test accuracy of IHC and MSI-based strategies to detect Lynch syndrome in people who have endometrial cancer, and the clinical and cost effectiveness of testing for Lynch syndrome amongst people who have been diagnosed with endometrial cancers. The key questions for this review are provided in the box below.

Key question 1

What are the test accuracy, test failure rates, and time to diagnosis of IHC and MSI-based strategies for detecting Lynch syndrome in people who have a diagnosis of endometrial cancer?

Sub questions

1a. What is the concordance between IHC and MSI-based strategies for detecting Lynch syndrome in people who have a diagnosis of endometrial cancer?

1b. What are the characteristics of discordant cases? (e.g. do people with a high risk according to MSI testing and a low risk according to IHC (or vice versa) have particular gene mutations, a family history of Lynch syndrome, different age profiles?)

2. What are the types and frequencies of MMR genetic mutations detected in people with endometrial cancer who are diagnosed with Lynch syndrome?

Key question 2

What are the benefits and harms of testing for Lynch syndrome amongst people who have endometrial cancer, and/or their relatives?

Sub questions

 What are the benefits and harms of colorectal cancer surveillance for people with Lynch syndrome identified following a diagnosis of endometrial cancer, and/or their relatives?
 What are the benefits and harms of gynaecological cancer surveillance for people with Lynch syndrome identified following a diagnosis of endometrial cancer, and/or their relatives?

Key question 3

What is the cost-effectiveness of testing for Lynch syndrome amongst people diagnosed with endometrial cancer using IHC and MSI-based strategies compared to the current pathway for the diagnosis of Lynch syndrome?

4. Methods for assessing test accuracy

What are the test accuracy, test failure rates, and time to diagnosis of IHC and MSI-based strategies for detecting Lynch syndrome in people who have a diagnosis of endometrial cancer?

Review sub questions:

1a. What is the concordance between IHC and MSI-based strategies for detecting Lynch syndrome in people who have a diagnosis of endometrial cancer?

1b. What are the characteristics of discordant cases? (e.g. do people with a high risk of Lynch syndrome according to MSI testing and a low risk according to IHC (or vice versa) have particular gene mutations, a family history of Lynch syndrome, different age profiles?)

2. What are the types and frequencies of MMR genetic mutations detected in people with endometrial cancer who have been diagnosed with Lynch syndrome?

Systematic review methods will follow the principles outlined in the Cochrane Handbook of Diagnostic Test Accuracy²⁹ and the NICE Diagnostic Assessment Programme manual.³⁰

4.1 Identification and selection of studies

4.1.1 Search strategy

The search strategy will comprise the following main elements:

- 1) Searching of electronic bibliographic databases,
- 2) Contacting experts in the field, and
- 3) Scrutiny of references of included studies and relevant systematic reviews.

A comprehensive search will be developed iteratively and undertaken in a range of relevant bibliographic databases. The search terms will relate to endometrial cancer and lynch syndrome. There will be no restrictions on date or language. Searches will be conducted in the following databases: MEDLINE All (Ovid); Embase (Ovid); Cochrane Database of Systematic Reviews (Wiley); CENTRAL (Wiley); Database of Abstracts of Reviews of Effects (DARE) (Centre for Reviews and Disseminations (CRD)); Health Technology Assessment (HTA) database (CRD/INAHTA); Science Citation Index and Conference Proceedings (Web of Science); PROSPERO International Prospective Register of Systematic Reviews (CRD). The search will be developed in MEDLINE (Ovid) and adapted as appropriate for other databases. A copy of the draft search strategy is provided in Appendix 1.

Records will be exported to EndNote X9, where duplicates will be systematically identified and removed.

4.1.2 Study eligibility criteria

Population	<u>All questions</u>		
	People with endometrial cancer with no known diagnosis of Lynch		
	syndrome		
Target condition	<u>All questions</u>		
	Lynch syndrome		
Intervention	<u>All questions</u>		
	Strategy 1: MSI-based testing without <i>MLH1</i> promoter hypermethylation		
	testing		
	Strategy 2: MSI-based testing with MLH1 promoter hypermethylation		
	testing		
	Strategy 3: IHC without <i>MLH1</i> promoter hypermethylation testing		
	Strategy 4: IHC with <i>MLH1</i> promoter hypermethylation testing		
	Strategy 5: MSI-based testing followed by IHC without MLH1 promoter		
	hypermethylation testing		
	Strategy 6: MSI-based testing followed by IHC with <i>MLH1</i> promoter		
	hypermethylation testing		
	Strategy 7: IHC followed by MSI-based testing without MLH1 promoter		
	hypermethylation testing		
	Strategy 8: IHC followed by MSI-based testing with MLH1 promoter		
	hypermethylation testing		
	Strategy 9: IHC and MSI-based tests consecutively without MLH1		
	promoter hypermethylation testing		

Studies that satisfy the following criteria will be included:

	Strategy 10: IHC and MSI-based tests consecutively with MLH1 promoter		
	hypermethylation testing		
Reference standard	All questions		
	Genetic verifications of constitutional mutations in the MMR genes		
	through: sequencing (including next-generation sequencing) and multiplex		
	ligation-dependent probe amplification. If there are insufficient studies		
	using these reference standards, we will include studies using other		
	diagnostic tests outlined in the Association for Clinical Genomic Science		
	best practice guidelines for genetic testing and diagnosis of Lynch		
	syndrome, i.e. array-based comparative genomic hybridization, and long-		
	range PCR ³¹		
Comparator	Key question		
· · · · · · · ·	No reflex testing		
	Sub questions 1a and 1b		
	IHC without MLH1 promoter hypermethylation testing		
	IHC with MLH1 promoter hypermethylation testing		
	MSI-based testing without MLH1 promoter hypermethylation testing		
	MSI-based testing with MLH1 promoter hypermethylation testing		
	Sub question 2		
	No reflex testing		
Outcome	Key question		
	Test accuracy, detection rate, sensitivity and specificity, predictive values,		
	likelihood ratios, diagnostic odds ratios, receiver operating characteristic		
	(ROC) curves and numbers of true positive, false positive, true negative,		
	false negative results, and number of Lynch syndrome diagnoses		
	Test failures (rates, and data on inconclusive, indeterminate, and excluded		
	samples, failure due to insufficient tissue or any other reason)		
	Time to diagnosis		
	1 Time from test being conducted to test result being given and/or		
	2 Time from test being conducted to diagnosis being given		
	2. This for congression of the second conducted to diagnosis being given		
	Sub question 1a		
	Concordance between IHC and MSI (fractions, kappa, % agreement)		
	Sub question 1b		
	Any available characteristics of the population or tumours, including		
	family history, and results of germline testing		

	Sub question 2 Types and frequencies of Lynch syndrome-related genetic mutations (MLH1, MSH2, MSH6, PMS2) in people newly diagnosed with Lynch syndrome after endometrial cancer, including results of MLH1 promoter hypermethylation testing
Study design	<u>Key question</u> All study designs will be included, including cross-sectional test accuracy studies, randomised controlled trials, cohort studies and case-control studies. Head-to-head (direct comparison) studies will be prioritised
	<u>Sub questions 1a and b</u> Head-to-head studies only: cross-sectional test accuracy studies, test quality or accuracy studies nested within RCTs or cohort studies, case-control studies, test sets
	Sub question 2 All study designs will be included, including randomised controlled trials, cross-sectional test accuracy studies, cohort studies and case-control studies
Publication type	<u>All questions</u> Peer reviewed papers Abstracts and manufacturer data will be included only if they provide numerical data and sufficient detail on methodology to enable assessment of study quality/risk of bias. Further, only data on outcomes that have not been reported in peer-reviewed full text papers will be extracted and reported.
Language	All questions English

Papers that fulfil the following criteria will be excluded:

Non-human studies, letters, editorials and communications. Qualitative studies. Studies of women who have pre-cancerous conditions of the uterus (i.e. atypical endometrial hyperplasia). Studies where more than 10% of the sample do not meet our inclusion criteria. Studies without extractable numerical data. Studies that provided insufficient information for assessment of methodological quality/risk of bias. Articles not available in the English language. Studies using index tests other than those specified in the inclusion criteria. Studies reporting the test accuracy of IHC and MSI-based testing strategies in the general population (estimates arising from the general population are not generalisable to people that are at higher risk of Lynch syndrome because of the different risk profile).

If sufficient head-to-head studies are identified that can provide meaningful analysis, other study designs will be excluded.

4.1.4 Review strategy

Two reviewers (CS, LAK/HF) will independently screen the titles and abstracts of records identified by the searches. Any disagreements will be resolved through discussion, or retrieval of the full publication. Potentially relevant publications will be obtained, and assessed independently by two reviewers (CS, LAK/HF) with a coding tool (using inclusion/exclusion criteria) that has been piloted on a subsample of papers. Disagreements will be resolved through consensus, with the inclusion of a third reviewer (HF/LAK, STP) if required. Records that are excluded at full text stage will be documented, including the reasons for their exclusion.

4.2 Extraction and study quality

4.2.1 Data extraction strategy

Two reviewers (CS, LAK/HF) will extract data independently, using a piloted data extraction form. Disagreements will be resolved through consensus, with the inclusion of a third reviewer (HF/LAK, STP) if required.

4.2.2 Assessment of study risk of bias

The risk of bias of test accuracy studies will be assessed using a modified QUADAS-2.³² Two reviewers (CS, LAK/HF) will independently assess study risks of bias. Disagreements will be resolved through consensus, with the inclusion of a third reviewer (HF/LAK, STP) if required. As recommended by the QUADAS-2 group, an overall quality score will not be determined.³² The results of each risk of bias item will be presented in table and graph form.

4.3 Methods of analysis/synthesis

Test accuracy results will be presented for testing strategies 1 – 10, comparing the index tests to the eligible reference standards. Test accuracy will not be assessed for strategy 11 as this approach does not include an index test. For studies that include an initial test followed by *MLH1* promoter hypermethylation testing, we will analyse data at each stage of the process, i.e. (1a) IHC alone, then (1b) IHC *plus MLH1* promoter hypermethylation testing, (2a) MSI-based testing alone, then (2b) MSI-based testing *plus MLH1* promoter hypermethylation testing. For IHC results, we will report results together and separately for each protein. For MSI results, we will report the panel used as per the papers. If possible, a subgroup analysis will also be undertaken on MSI-low and MSI-high patients. Our main analysis will assume MSI low are test negative. Furthermore, if data permit, we will conduct subgroup analyses of test accuracy by (1) age (under vs over 70 years) and (2) amongst

people who have had a prior Lynch syndrome-related cancer (as defined in NHS England's National Genomic Test Directory, "Testing Criteria for Rare and Inherited Disease"). If enough homogeneous studies are available then a meta-analysis will be undertaken. Otherwise, a narrative summary of the evidence will be presented.

Variants of uncertain clinical significance on germline testing are not considered to have Lynch syndrome in our test accuracy analysis. The EAG will record how many of these there are for scenario analysis in the economic modelling, considering either all or none as having Lynch syndrome. In practice, patients with a negative germline test result (with no somatic cause of the tumour identified) but a positive index test may be considered to have Lynch-like syndrome (also known as putative or cryptic Lynch syndrome) and undergo further investigation or surveillance. In particular, further investigation is undertaken if there is family history of Lynch syndrome. Due to this, the EAG will descriptively record the characteristics of these cases such as family history, IHC results and discordant cases between the two index tests. This will provide contextual information about the possibility of Lynch-like syndrome, and variants of uncertain clinical significance. However, for the reporting of test accuracy data, germline testing using sequencing (including NGS) and MLPA will be considered the primary reference standard. If there are insufficient studies using these reference standards, we will include studies using other diagnostic tests outlined in the Association for Clinical Genomic Science best practice guidelines for genetic testing and diagnosis of Lynch syndrome, i.e. array-based comparative genomic hybridization, and long-range PCR.³¹ The uncertainty around the effectiveness of germline testing to diagnose all cases of Lynch syndrome (see above regarding Lynch-like syndrome) is a potential weakness of the reference standard and a limitation of this review. As a sub-analysis, for studies that report extra steps to the reference standard (e.g. sequencing of tumours, or incorporating family history data), we will make a record of the additional tests that are used. If sufficient data are available, we will compare the results of these multi-stage reference standards to the results of germline testing for MLH1, MSH2, MSH6, and PMS2 using sequencing (including NGS) and MLPA.

5. Methods for assessing clinical effectiveness

Key question 2

What are the benefits and harms of testing for Lynch syndrome amongst people who have endometrial cancer, and/or their relatives?

Sub questions

1. What are the benefits and harms of colorectal cancer surveillance for people with Lynch syndrome identified following a diagnosis of endometrial cancer, and/or their relatives?

2. What are the benefits and harms of gynaecological cancer surveillance for people with Lynch syndrome identified following a diagnosis of endometrial cancer, and/or their relatives?

This question is to identify 'end-to-end studies', or 'test-treat trials'. End-to-end studies follow people from initial testing to treatment and final outcomes. These studies can remove the need for separate searches for model parameters for cost-effectiveness modelling.³⁰ We will conduct a literature search to identify end-to-end studies of testing for Lynch syndrome amongst people who have been diagnosed with endometrial cancer, and/or their relatives. The same review searches and methods that will be used for the test accuracy question (see section 4) will be employed to address this question. The sub-questions are designed to identify the benefits and harms of the two main surveillance strategies which would be employed after identification with Lynch syndrome. These will be used in a linked-evidence approach if no end-to-end studies are found.

Systematic review methods will follow the principles outlined in the Centre for Reviews and Dissemination (CRD) guidance for undertaking reviews in health care³³ and the NICE Diagnostic Assessment Programme manual.³⁰

5.1 Identification and selection of studies

5.1.1 Search strategy

The same search strategy as described in the methods for test accuracy will be used (see section 4.1).

5.1.2 Study eligibility criteria

Studies that satisfy the following criteria will be included:

Population	Key question	
- T	People with endometrial cancer with no known diagnosis of Lynch	
	syndrome, and/or their relatives	
Sub questions 1 and 2		
	People with endometrial cancer who have also been diagnosed with Lynch	
	syndrome, and/or their relatives	
Target condition	Key question	
	Lynch syndrome	
	Sub question 1	
	Colorectal cancer	
	Sub question 2	
	Gynaecological cancers (endometrial, ovarian, cervical, vaginal and vulval)	

Intervention	Key question MSI-based testing (with/without MLH1 promoter hypermethylation testing) followed by germline testing (sequencing, NGS, MLPA. If there are insufficient studies using these reference standards, we will include studies using array-based comparative genomic hybridization, and long- range PCR) for Lynch syndrome-related mutations (MLH1, MSH2, MSH6, PMS2) followed by any intervention for Lynch syndrome including preventative hysterectomy, aspirin, surveillance/testing for colorectal cancer or gynaecological cancers
	IHC (with/without MLH1 promoter hypermethylation testing) followed by germline testing (sequencing, NGS, MLPA. If there are insufficient studies using these reference standards, we will include studies using array-based comparative genomic hybridization, and long-range PCR) for Lynch syndrome-related mutations (MLH1, MSH2, MSH6, PMS2) followed by any intervention for Lynch syndrome including preventative hysterectomy, aspirin, surveillance/testing for colorectal cancer or gynaecological cancers
	Combinations of MSI-based testing and IHC (with/without MLH1 promoter hypermethylation testing) followed by germline testing (sequencing, NGS, MLPA. If there are insufficient studies using these reference standards, we will include studies using array-based comparative genomic hybridization, and long-range PCR) for Lynch syndrome-related mutations (MLH1, MSH2, MSH6, PMS2) followed by any intervention for Lynch syndrome including preventative hysterectomy, aspirin, surveillance/testing for colorectal cancer or gynaecological cancers
	Sub question 1 Surveillance/testing for colorectal cancer Sub question 2
	Surveillance/testing for gynaecological cancers (endometrial, ovarian, cervical, vaginal and vulval)
Comparator	Key question No testing for Lynch syndrome
	Sub questions 1 and 2 No surveillance/testing
Outcome	Key questionMortalityMorbidityType and number of Lynch syndrome-related cancersHealth-related quality of life using validated toolsAnxiety using validated tools

	Depression using validated tools		
	Change in patient management		
	Number of cascade tests on first/second-degree relatives		
	Morbidity and mortality of first/second-degree relatives		
	Number of interventions related to surveillance for Lynch syndrome relations		
	cancers		
	Number of risk reducing interventions for Lynch syndrome related cancer		
	Sub question 1		
	Colorectal cancer incidence		
	Number of interventions related to surveillance for Lvnch syndrome-		
	related cancers		
	Number of risk reducing interventions for Lynch syndrome-related cancer		
	Colorectal cancer-related mortality		
	Colorectal cancer-related morbidity		
	Health-related quality of life using validated tools		
	Anxiety using validated tools		
	Depression using validated tools		
	Change in patient management		
	Sub question 2		
	Gynaecological cancer incidence (overall and by type)		
	Number of interventions related to surveillance for Lynch syndrome-		
	related cancers		
	Number of risk reducing interventions for Lynch syndrome-related cancer		
	Gynaecological cancer-related mortality (overall and by type)		
	Gynaecological cancer-related morbidity (overall, and by type)		
	Health-related quality of life using validated tools		
	Anxiety using validated tools		
	Depression using validated tools		
	Change in patient management		
	Change in patient management		
Study design	All questions		
Study design	Randomised controlled trials		
	Controlled trials		
Publication type	All questions		
	Peer reviewed papers		
	Abstracts and manufacturer data will be included only if they provide		
	numerical data and sufficient detail on methodology to enable assessment		
	of study quality/risk of bias. Further, only data on outcomes that have not		
	been reported in peer-reviewed full text napers will be extracted and		
	reported in peer reviewed full text pupers will be extracted and		
Language	All questions		
	English		

Papers that fulfil the following criteria will be excluded:

Non-human studies, letters, editorials and communications. Qualitative studies. Studies of women who have pre-cancerous conditions of the uterus (i.e. atypical endometrial hyperplasia). Studies where more than 10% of the sample do not meet our inclusion criteria. Studies without extractable numerical data. Studies that provided insufficient information for assessment of methodological quality/risk of bias. Articles not available in the English language. Studies using index tests other than those specified in the inclusion criteria.

5.1.3 Review strategy

Two reviewers (CS, LAK/HF) will independently screen the titles and abstracts of records identified by the searches. Any disagreements will be resolved through discussion, or retrieval of the full publication. Potentially relevant publications will be obtained, and assessed independently by two reviewers (CS, LAK/HF) with a coding tool (using inclusion/exclusion criteria) that has been piloted on a subsample of papers. Disagreements will be resolved through consensus, with the inclusion of a third reviewer (HF/LAK, STP) if required. Records that are excluded at full text stage will be documented, including the reasons for their exclusion.

5.2 Extraction and study quality

5.2.1 Data extraction strategy

Two reviewers (CS, LAK/HF) will extract data independently, using a piloted data extraction form. Disagreements will be resolved through consensus, with the inclusion of a third reviewer (HF/LAK, STP) if required.

5.2.2 Assessment of study risk of bias

The risk of bias of randomised control trials will be assessed using the Cochrane revised tool to assess risk of bias in randomized trials (RoB 2).³⁴ Risk of bias in controlled trials will be assessed using the Cochrane risk of bias in non-randomized studies of interventions (ROBINS-I) tool.³⁵ Two reviewers (CS, LAK/HF) will independently assess study risks of bias. Disagreements will be resolved through consensus, with the inclusion of a third reviewer (HF/LAK, STP) if required.

5.3 Methods of analysis/synthesis

We will use the following effect measures:

• Hazard ratio (HR) for time-to-event data (e.g. time to gynaecological cancer specific mortality)

- Risk ratio dichotomous outcomes (e.g. colorectal cancer incidence)
- Mean difference between arms for continuous outcomes (e.g. health-related quality of life).

We will not impute missing outcome data. We will perform the analysis based on the available data. If data permits and there is evidence of substantial heterogeneity (i.e. p value < 0.1 or I² > 50%) we will investigate and report the possible reasons for heterogeneity. If data permits and studies are clinically similar, we will pool the results in meta-analyses. For dichotomous outcomes, we will calculate the risk ratio and the 95% confidence interval for each study and then pool the studies. For time-to-event data we will pool the hazard ratios. For continuous outcomes, we will pool the mean difference and the 95% confidence interval at the end of follow-up if studies measure the outcome on the same scale. If studies measure the outcome using different scales we will pool using the standardised mean difference and the 95% confidence interval. If data do not permit a pooled analysis then we will conduct a narrative synthesis.

Methods for assessing cost-effectiveness

Key question 3

What is the cost-effectiveness of testing for Lynch syndrome amongst people diagnosed with endometrial cancer using immunohistochemistry and microsatellite instability-based strategies compared to the current pathway for the diagnosis of Lynch syndrome?

6.1 Identification and selection of studies

6.1.1 Search strategy

A comprehensive search of the literature for published economic evaluations, cost studies and healthrelated quality of life studies (HRQoL) will be performed. The database searches will be developed iteratively and combine terms for Lynch syndrome and economic/cost/HRQoL. The search will be informed by the strategy developed for the clinical effectiveness review and published economic and HRQoL search filters. This strategy may be further refined and other appropriate limits may be added. Databases will include:

MEDLINE All (Ovid);

Excerpta Medica database (Embase) (Ovid); National Health Service Economic Evaluation Database (NHS EED) and Health Technology Assessment (HTA) database (CRD); Science Citation Index and Conference Proceedings Science (Web of Science); Cost-Effectiveness Analysis (CEA) registry; EconPapers (Research Papers in Economics (RePEc)); and School of Health and Related Research Health Utilities Database (ScHARRHUD). The reference lists of included studies will be checked. The search will be developed in MEDLINE (Ovid) and adapted as appropriate for other databases.

Records will be exported to EndNote X9, where duplicates will be systematically identified and removed.

Additional searches will be performed where necessary to identify other relevant inputs (e.g. incidence of Lynch cancers, resource use and costs, utility values, or survival analysis information) to support building the economic model.

Where direct evidence is unavailable for different testing strategies, or where such a comparison is not well supported with evidence, a linked approach to evidence will be considered in which evidence of clinical effectiveness is taken from studies using alternative test methodology and an assessment is made of the relative performance this methodology relative to the testing strategies for Lynch syndrome.

6.1.2. Review strategy

All records retrieved will be screened independently by two reviewers at title/abstract stage, of which potentially relevant records will be further examined at full-text. Any disagreements between the reviewers will be resolved by a discussion, or recourse to a third reviewer if an agreement cannot be reached.

6.2 Extraction and study quality

6.2.1 Data extraction strategy

Information will be extracted by two reviewers independently, using a pre-piloted data extraction form for the full economic evaluation studies. The data extraction form will be developed to summarise the main characteristics of the studies and to capture useful information for the economic model. From each paper included in the systematic review, we will extract information about study details (title, author and year of study), baseline characteristics (population, intervention, comparator and outcomes), methods (study perspective, time horizon, discount rate, measure of effectiveness current, assumptions and analytical methods), results (study parameters, base-case and sensitivity analysis results), discussion (study findings, limitations of the models and generalisability), other (source of funding and conflicts of interests), overall reviewer comments and conclusion (author's and reviewer's). Each reviewer will cross-check each other's extractions, with any discrepancies resolved by discussion, or recourse to a third reviewer if an agreement cannot be reached.

6.2.2 Assessment of study methodological quality

The quality of any full economic evaluation studies will be assessed using the consolidated health economic evaluation reporting standards (CHEERS) checklist.³⁶ Any studies using an economic model will be further assessed against the framework for the quality assessment of decision analytic modelling developed by Philips and colleagues.³⁷

6.3 Methods of analysis/synthesis

Due to the nature of economic analyses (different aims/objectives, study designs, populations, and methods) these findings from individual studies will be compared narratively, and recommendations for future economic analyses will be discussed.

Evaluation of costs, health-related quality of life and cost-effectiveness

Model structure

If appropriate model-based cost-effectiveness studies addressing the review question are not found, a de novo economic model will be constructed. In constructing the economic model, we will consult the previous Health Technology Assessment (HTA) report undertaken by Snowsill and colleagues.¹⁰ These authors developed a decision analytical model which compared tumour-based strategies, direct mutation testing and no testing to identify Lynch syndrome in people with colorectal cancer. The model comprised two stages, a diagnostic and a management stage, which were used to simulate different pathways for a hypothetical cohort of people with colorectal cancer being screened for Lynch syndrome. The first stage used a decision tree structure to estimate the resource use and costs of diagnosis, and the number of probands and their first relatives who would be diagnosed with Lynch syndrome. The first stage of the model considered the different treatment (type of surgery, radiotherapy, hormone therapy and targeted therapy) options available to treat endometrial cancer. The second stage used an individual patient-level model to simulate the long-term costs and benefits (life-years and QALYs accrued) associated with management and surveillance, and prophylactic treatment for probands and relatives with Lynch syndrome.

The development of the model will be an iterative process. First, we will develop a conceptual model, with consultation with clinical experts. The conceptual model will be used to identify the information required to parameterise the model. We anticipate that parameterisation will be driven by the findings from the clinical effectiveness systematic review and supported by clinical expert opinion. We anticipate that the model will comprise a decision tree linked to a Markov state decision analytical model (cohort or individual).

Strategies for inclusion within the diagnostic component of the model are:

23

- 1. MSI testing followed by germline testing for Lynch syndrome-related mutations
- 2. MSI testing followed by *MLH1* promoter hypermethylation testing, followed by germline testing for Lynch syndrome-related mutations
- 3. IHC MMR testing followed by germline testing for Lynch syndrome-related mutations
- 4. IHC MMR testing followed by *MLH1* promoter hypermethylation testing, followed by germline testing for Lynch syndrome-related mutations
- 5. MSI followed by IHC then germline for Lynch syndrome-related mutations
- 6. MSI followed by IHC plus *MLH1* hypermethylation then germline for Lynch syndromerelated mutations
- 7. IHC followed by MSI then germline for Lynch syndrome-related mutations
- 8. IHC followed by MSI plus *MLH1* hypermethylation then germline for Lynch syndromerelated mutations
- 9. MSI and IHC done simultaneously then germline testing for Lynch syndrome-related mutations
- MSI and IHC done simultaneously plus *MLH1* hypermethylation testing then germline for Lynch syndrome-related mutations
- 11. Germline testing for Lynch syndrome-related mutations

These strategies will be compared against no testing for Lynch syndrome-related mutations.

With respect to strategies including MSI testing, the EAG will consider the variants of index tests identified from the literature and used as appropriate for evaluation.

Resource use and costs

As part of the framework to undertake the economic analysis, information will be required about the resource use and costs associated with the testing strategies used to identify Lynch syndrome in people with endometrial cancer. Additionally, resource use and costs will be required for the long-term management and surveillance of people with Lynch syndrome and their relatives and costs associated with the cancers they might have. Probands with Lynch syndrome will be offered surveillance for colorectal cancer (and if management of endometrial cancer is fertility sparing monitoring for endometrial and ovarian cancer) and risk-reducing interventions (e.g. aspirin as a chemopreventative treatment). Probands without Lynch syndrome will follow the UK Bowel cancer screening programme. Additionally, relatives who are diagnosed with Lynch syndrome through testing, will be offered surveillance for colorectal and gynaecological cancers (endometrial and ovarian) and risk-reducing interventions (aspirin as chemopreventative treatment and hysterectomy with or without bilateral salpingo-oophorectomy as a surgical strategy) for Lynch syndrome. Relatives without Lynch syndrome will follow the usual NHS bowel screening programme.

Of note, probands diagnosed with Lynch-like syndrome (also termed putative lynch syndrome in previous DAR¹⁰ will be modelled in our base case under the assumptions that 1) Somatic tumour testing is required to rule out sporadic cancer and achieve Lynch-like diagnosis, and 2) Cascade testing in relatives of Lynch-like diagnosed probands is not assumed to be the same as that of confirmed probands. Cascade testing is pursued among first degree relatives only. Risk of developing CRC in people with Lynch-like syndrome will be assumed the same as those with a definitive Lynch syndrome diagnosis.

Health outcomes

Three outcome measures will be used in the economic analysis, number of relatives identified with Lynch syndrome, life-years (LY) and quality-adjusted life-years (QALYs) gained. LY and QALYs gained will be calculated from survival information, including incidence and survival of endometrial cancer and colorectal cancer, and utility values obtained from the literature and other sources (e.g. elicited from experts). QALYs accrued will be derived based on the utility payoff assigned to the health states occupied along the management pathway. Under each testing strategy the expected mean benefits yielded are summed over the model time horizon and discounted at a 3.5% per annum rate.

Cost-effectiveness analysis

The cost-effectiveness analysis will consider the ratio between the costs incurred and benefits accrued for each testing strategy from the NHS and PSS perspective in a secondary/tertiary care setting. The results of the analysis will be presented in terms of an incremental cost-effectiveness analysis (ICER), where each testing strategy will be ranked, excluding options that were dominated or extendedly dominated, with results expressed as cost per QALY. We will also present secondary outcome results in the form of cost per asymptomatic person identified with Lynch syndrome. We will use univariate one-way sensitivity analysis to explore the impact of varying one parameter at a time, whilst keeping all other inputs constant to assess the robustness of the model, with results presented in the form of a tornado diagram. We anticipate undertaking scenario analyses around the number of relatives per proband, excluding benefits associated with relatives, including surveillance for colorectal cancer only, increasing/decreasing the incidence of colorectal cancer, increasing/decreasing the incidence of gynaecological cancers and treating MSI low results as positive and negative. Other scenario analyses will be undertaken as required through model development. Subgroup analysis for people with endometrial cancer under 70 years old and people with endometrial cancer who have previously had a Lynch syndrome related cancer, without germline testing, will be conducted if data permits. Probabilistic sensitivity analysis will be used to determine the impact of joint parameter uncertainty. In probabilistic sensitivity analysis, model parameters are assigned a distribution reflecting the

25

amount and pattern of its variation, and cost-effectiveness results are calculated by simultaneously selecting random values from each distribution. This process is repeated a number of times, with the simulations plotted on an incremental cost-effectiveness plane; each point representing uncertainty in the incremental mean costs and QALYs between the strategies being compared. The results from these simulations will be used to obtain cost-effectiveness acceptability curves (CEAC), which illustrate the effect of sampling uncertainty, and presents the probability that an intervention is optimal at a range of willingness-to-pay (WTP) threshold values.³⁸

Areas anticipated to be beyond the scope of the assessment

The EAG's model will consider people with endometrial cancer, which is cancer of the lining of the womb (uterus). Explicitly, we will not consider precancerous conditions that can develop in the lining of the uterus (endometrium) within the model. For example, atypical endometrial hyperplasia is not yet cancer, but if left untreated, there is an increased risk that abnormal cells may become cancerous. To include this population into the model would require the following information:

- Amending the search for the clinical effectiveness review to include terms for atypical endometrial hyperplasia ('atypical hyperplasia' is too broad and would find results from other cancers)
- Incidence of Lynch syndrome in people with atypical endometrial hyperplasia
- How index tests perform in biopsy samples obtained from people with atypical endometrial hyperplasia
- Management/treatment (e.g. procedures) available/offered to people with atypical endometrial hyperplasia and the effectiveness of these strategies
- Effectiveness of prophylaxis and screening in people with atypical endometrial hyperplasia including those who decline prophylactic treatment
- Effectiveness of surveillance of other cancers (e.g. colorectal cancer and ovarian cancer) specifically in patients with atypical endometrial hyperplasia
- Health-related quality of life specifically in patients with atypical endometrial hyperplasia

7. Handling of information from manufacturers

All data submitted by the manufacturers/sponsors/stakeholders will only be considered if received by the External Assessment Group before 1st November 2019. Data that arrives after this date will not be considered. We will extract and quality appraise any data that meets the inclusion criteria, as stated in the methods section of this protocol.

Any 'commercial in confidence' data that is provided by manufacturers, academics, clinicians, or stakeholders, and specified as such, will be highlighted in blue and underlined in the assessment report (followed by company name in parentheses). Any 'academic in confidence' data that is provided by manufacturers, and specified as such, will be highlighted in yellow and underlined in the assessment report. All confidential data used in the cost-effectiveness models will also be highlighted. If confidential information is included in the model, we will provide a model with 'dummy variable values' for the confidential values (i.e. using non-confidential values).

8. Competing interests of authors and advisors

None of the authors have any competing interests.

9. Timetable/milestones

Draft assessment protocol	11.07.19
Final protocol	7.08.19
Progress report	31.10.19
Draft assessment report	2.01.20
Final assessment report	28.01.20

10. Team members' contributions

Warwick Evidence is an External Assessment Group located within Warwick Medical School. Warwick Evidence brings together experts in clinical and cost effectiveness reviewing, medical statistics, health economics and modelling. The team planned for the work include:

Name: Chris Stinton Title: Senior Research Fellow Address: Warwick Medical School, University of Warwick, CV4 7AL Tel: 02476 574 701 Email: <u>c.stinton@warwick.ac.uk</u> Contribution: protocol development, lead clinical effectiveness reviewer, writing up

Name: Mary Jordan Title: Research Fellow Address: Warwick Medical School, University of Warwick, CV4 7AL Tel: 02476 573855 Email: <u>Mary.Jordan@warwick.ac.uk</u> Contribution: Health Economics Name: Mr. Peter Auguste
Title: Research Fellow
Address: Warwick Medical School, University of Warwick, Coventry CV4 7AL
Tel: 02476 150648
Email: p.auguste@warwick.ac.uk
Contribution: Protocol development, systematic review of the health economic literature, health economic modelling, and report writing

Name: Hannah Fraser Title: Research Associate Address: Warwick Medical School, University of Warwick, CV4 7AL Tel: 02476 150063 E mail: <u>H.Fraser@warwick.ac.uk</u> Contribution: Protocol development, second clinical effectiveness second reviewer

Name: Rachel Court
Title: Information Specialist
Address: Warwick Medical School, University of Warwick, CV4 7AL
Tel: 02476 574639
Email: <u>r.a.court@warwick.ac.uk</u>
Contribution: Develop the search strategies, undertake searches, write the search methods sections of the draft and final versions of the report and manage references.

Name: Lena Al-Khudairy Title: Senior Research Fellow Address: Warwick Medical School, University of Warwick, CV4 7AL Tel: 024 761 51762 Email: Lena.al-khudairy@warwick.ac.uk Contribution: Supporting the clinical effectiveness team

Name: Jason Madan Title: Professor of Health Economics Address: Warwick Clinical Trials Unit, University of Warwick, Coventry, CV47AL Tel: 02476 151254 Email: J.J.Madan@warwick.ac.uk

Contribution: Protocol development, coordinate health economic modelling, and report writing

Name: Dr Sian Taylor-Phillips Title: Associate Professor of Screening and Test evaluation Address: University of Warwick, Coventry, CV47AL Tel: 02476 575882 Email: <u>s.taylor-phillips@warwick.ac.uk</u> Contribution: Project lead, design and planning of the review, implementation and write up.

9.1 Expert advisors

Name: Dimitris Grammatopoulos Title: Professor of Molecular Medicine, Consultant in Clinical Biochemistry Address: University of Warwick, Coventry, CV47AL Tel: 02476 968661 Email: <u>d.grammatopoulos@warwick.ac.uk</u> Contribution: Clinical advisor on testing strategies

Appendix 1. Draft search strategy Database: Ovid MEDLINE(R) ALL <1946 to July 08, 2019> Search Strategy:

1 uterine neoplasms/ (40206)

2 exp endometrial neoplasms/ (20524)

3 ((uter* or endomet* or womb) adj4 (neoplas* or cancer* or carcinom* or adenocarcinom* or

tumour* or tumor* or malignan* or dysplasis* or disease* or adenocanthom* or sarcom*)).ti,ab,kf. (66078)

4 1 or 2 or 3 (91903)

5 exp Colorectal Neoplasms, Hereditary Nonpolyposis/ (4398)

6 (lynch* adj3 syndrome*).ti,ab,kf. (2913)

7 ((lynch* adj3 famil*) and (cancer* or neoplasm*)).ti,ab,kf. (357)

8 (((familial or hereditary or inherit*) adj3 (colon* or colorectal*)) and (cancer or neoplasm*)).ti,ab,kf. (4574)

9 (((hereditary or familial) adj3 (nonpolyposis or non-polyposis)) and (colon* or colorectal*)).ti,ab,kf. (3193)

10 ((hereditary adj3 (cancer or neoplasm*)) and (colon* or colorectal*)).ti,ab,kf. (2874)

11 (familial adj3 (colon* or colorectal*)).ti,ab,kf. (1168)

- 12 HNPCC.ti,ab,kf. (2231)
- 13 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 (8071)
- 14 (EPCAM? or MLH1 or MSH2 or MSH6 or PMS2 or hMSH2 or hMLH1 or hPMS2 or hMSH6).ti,ab,kf. (9585)
- 15 (colon* or colorectal* or lynch* or HNPCC or hereditary).ti,ab,kf. (610298)
- 16 14 and 15 (4450)
- 17 ((mismatch repair* or MMR or EPCAM? or MLH1 or MSH2 or MSH6 or PMS2 or hMSH2 or

hMLH1 or hPMS2 or hMSH6) adj3 (germline or DNA* or gene* or mutation* or

deficienc*)).ti,ab,kf. (8243)

- 18 Amsterdam criteria.ti,ab,kf. (410)
- 19 13 or 16 or 17 or 18 (14127)
- 20 4 and 19 (1535)

References

1. NICE: Molecular testing strategies for Lynch syndrome in people with colorectal cancer, 2017

2. Møller P, Seppälä T, Bernstein I, et al: Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 66:464-472, 2017

3. Lu KH, Loose DS, Yates MS, et al: Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (Phila) 6:774-81, 2013

4. Roett MA: Genital Cancers in Women: Uterine Cancer. FP Essent 438:11-7, 2015

5. Cancer Research UK: Uterine cancer statistics, 2016

6. Office of National Statistics: Cancer survival in England: national estimates for patients followed up to 2017, 2017

7. Ali AT: Reproductive factors and the risk of endometrial cancer. Int J Gynecol Cancer 24:384-93, 2014

8. Trabert B, Wentzensen N, Yang HP, et al: Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? International journal of cancer 132:417-426, 2013

9. Raglan O, Kalliala I, Markozannes G, et al: Risk factors for endometrial cancer: An umbrella review of the literature. Int J Cancer, 2018

10. Snowsill T, Coelho H, Huxley N, et al: Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. Health Technol Assess 21:1-238, 2017

11. Kuiper RP, Vissers LE, Venkatachalam R, et al: Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 32:407-14, 2011

12. Moller P, Seppala TT, Bernstein I, et al: Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 67:1306-1316, 2018

13. Hampel H, Frankel W, Panescu J, et al: Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66:7810-7, 2006

14. Lu KH, Schorge JO, Rodabaugh KJ, et al: Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25:5158-64, 2007

15. Shia J: Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. The Journal of molecular diagnostics 10:293-300, 2008

16. Hegde M, Ferber M, Mao R, et al: ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Genet Med 16:101-16, 2014

17. Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-8, 2004

18. Castillejo A, Hernandez-Illan E, Rodriguez-Soler M, et al: Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer. J Med Genet 52:498-502, 2015

19. Cho KR, Cooper K, Croce S, et al: International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 38 Suppl 1:S114-S122, 2019

20. Crosbie EJ, Ryan NAJ, Arends MJ, et al: The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genet Med, 2019

21. NHS England: Testing Criteria for Rare and Inherited Disease, National Genomic Test Directory, 2019

22. Sundar S, Balega J, Crosbie E, et al: BGCS uterine cancer guidelines: Recommendations for practice. Eur J Obstet Gynecol Reprod Biol 213:71-97, 2017

23. Vasen HF, Blanco I, Aktan-Collan K, et al: Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62:812-23, 2013

24. Kulkarni A, AF B: Management of Women with a Genetic Predisposition to Gynaecological Cancers: Scientific Impact Paper No. 48, Royal College of Obstetricians & Gynaecologists, 2015

25. Burn J, Gerdes AM, Macrae F, et al: Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081-7, 2011

26. Schmeler KM, Lynch HT, Chen LM, et al: Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261-9, 2006

27. Barrow P, Khan M, Lalloo F, et al: Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br J Surg 100:1719-31, 2013

28. Renkonen-Sinisalo L, Butzow R, Leminen A, et al: Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 120:821-4, 2007

29. Cochrane: Handbook for Diagnostic Test Accuracy Reviews, 2019

30. National Institute for Health and Clinical Excellence: Diagnostics Assessment Programme manual. Manchester, National Institute for Health and Clinical Excellence, 2011

31. Association for Clinical Genomic Science: ACGS best practice guidelines for genetic testing and diagnosis of Lynch syndrome, Association fo Clinical Genomic Science, 2016

32. Whiting PF, Rutjes AW, Westwood ME, et al: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529-36, 2011

33. Centre for Reviews and Dissemination: CRD's guidance for undertaking reviews in health care. York, Centre for Reviews and Dissemination, 2015

34. Higgins J, Sterne J, Savović J, et al: A revised tool for assessing risk of bias in randomized trials in Chandler J, McKenzie J, Boutron I, et al (eds): Cochrane Methods, 2016

35. Sterne JA, Hernán MA, Reeves BC, et al: ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. 355:i4919, 2016

36. Husereau D, Drummond M, Petrou S, et al: Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Eur J Health Econ 14:367-72, 2013

37. Philips Z, Ginnelly L, Sculpher M, et al: Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 8:iii-iv, ix-xi, 1-158, 2004

38. Fenwick E, Claxton K, Sculpher M: Representing uncertainty: the role of costeffectiveness acceptability curves. Health Econ 10:779-87, 2001